NO20002450L - Sammenstilling av aktive bestanddeler, særlig tetrahydropyridiner og acetylcholinesterase-inhiberende midler, for behandling av senil demens av Alzheimer-type - Google Patents

Sammenstilling av aktive bestanddeler, særlig tetrahydropyridiner og acetylcholinesterase-inhiberende midler, for behandling av senil demens av Alzheimer-type

Info

Publication number
NO20002450L
NO20002450L NO20002450A NO20002450A NO20002450L NO 20002450 L NO20002450 L NO 20002450L NO 20002450 A NO20002450 A NO 20002450A NO 20002450 A NO20002450 A NO 20002450A NO 20002450 L NO20002450 L NO 20002450L
Authority
NO
Norway
Prior art keywords
tetrahydropyridines
alzheimer
treatment
composition
type
Prior art date
Application number
NO20002450A
Other languages
English (en)
Norwegian (no)
Other versions
NO20002450D0 (no
Inventor
Jean-Pierre Maffrand
Philippe Soubrie
Jean-Paul Terranova
Original Assignee
Sanofi Synthelabo
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from FR9714324A external-priority patent/FR2771006B1/fr
Priority claimed from FR9714322A external-priority patent/FR2771007B1/fr
Application filed by Sanofi Synthelabo filed Critical Sanofi Synthelabo
Publication of NO20002450D0 publication Critical patent/NO20002450D0/no
Publication of NO20002450L publication Critical patent/NO20002450L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/64—Sulfonylureas, e.g. glibenclamide, tolbutamide, chlorpropamide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
NO20002450A 1997-11-14 2000-05-11 Sammenstilling av aktive bestanddeler, særlig tetrahydropyridiner og acetylcholinesterase-inhiberende midler, for behandling av senil demens av Alzheimer-type NO20002450L (no)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
FR9714324A FR2771006B1 (fr) 1997-11-14 1997-11-14 Association de principes actifs pour le traitement de la demence senile du type alzheimer
FR9714322A FR2771007B1 (fr) 1997-11-14 1997-11-14 Association de principes actifs pour le traitement de la demence senile du type alzheimer
PCT/FR1998/002384 WO1999025363A1 (fr) 1997-11-14 1998-11-09 Association de principes actifs, notamment de tetrahydropyridines et d'agents inhibiteurs de l'acetylcholinesterase, pour le traitement de la demence senile du type alzheimer

Publications (2)

Publication Number Publication Date
NO20002450D0 NO20002450D0 (no) 2000-05-11
NO20002450L true NO20002450L (no) 2000-07-14

Family

ID=26233932

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20002450A NO20002450L (no) 1997-11-14 2000-05-11 Sammenstilling av aktive bestanddeler, særlig tetrahydropyridiner og acetylcholinesterase-inhiberende midler, for behandling av senil demens av Alzheimer-type

Country Status (27)

Country Link
EP (1) EP1030671A1 (pl)
JP (1) JP2001523642A (pl)
KR (1) KR100599350B1 (pl)
CN (1) CN1243540C (pl)
AU (1) AU743228B2 (pl)
BG (1) BG64819B1 (pl)
BR (1) BR9814035A (pl)
CA (1) CA2309966A1 (pl)
CO (1) CO4980891A1 (pl)
DZ (1) DZ2649A1 (pl)
EA (1) EA003255B1 (pl)
EE (1) EE04235B1 (pl)
HU (1) HUP0100098A3 (pl)
ID (1) ID24933A (pl)
IL (2) IL136122A0 (pl)
IS (1) IS5482A (pl)
MY (1) MY120461A (pl)
NO (1) NO20002450L (pl)
NZ (1) NZ504420A (pl)
OA (1) OA11464A (pl)
PL (1) PL194597B1 (pl)
SA (1) SA98190747B1 (pl)
SK (1) SK286040B6 (pl)
TR (1) TR200001262T2 (pl)
TW (1) TW585766B (pl)
UY (1) UY25247A1 (pl)
WO (1) WO1999025363A1 (pl)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
USRE42327E1 (en) 2002-06-14 2011-05-03 Toyama Chemical Co., Ltd. Medicinal compositions improving brain function and method for improving brain function
DK1529116T3 (da) * 2002-08-07 2009-11-09 Novartis Ag Fremgangsmåde til forudsigelse af respons på behandling med rivastigmin baseret på ApoE-genotypen hos demenspatienter
CN1520818A (zh) * 2003-02-09 2004-08-18 山东绿叶天然药物研究开发有限公司 治疗老年性痴呆的胆碱酯酶抑制剂药物组合物
AU2005320547B2 (en) 2004-12-27 2009-02-05 Eisai R & D Management Co., Ltd. Method for stabilizing anti-dementia drug
DK3099296T3 (en) 2014-01-31 2019-04-15 Cognition Therapeutics Inc ISO-INDOLINE DERIVATIVES, COMPOSITIONS AND METHODS FOR TREATING NEURODEGENERATIVE DISEASE
IL270251B2 (en) * 2017-05-15 2025-01-01 Cognition Therapeutics Inc 1-Phenyl-1,1-dimethyl-2-(piperidinyl/pyrrolidinyl/piperazinyl)ethane derivatives and pharmaceutical preparations containing them
KR102224917B1 (ko) 2018-03-20 2021-03-09 (주)인벤티지랩 인지 장애 관련 질병의 예방 또는 치료용 약학적 조성물의 제조 방법 및 이의 제조 방법으로 제조된 인지 장애 관련 질병의 예방 또는 치료용 약학적 조성물
WO2019182319A1 (ko) * 2018-03-20 2019-09-26 (주)인벤티지랩 인지 장애 관련 질병의 예방 또는 치료용 약학적 조성물의 제조 방법 및 이의 제조 방법으로 제조된 인지 장애 관련 질병의 예방 또는 치료용 약학적 조성물
CN109265391B (zh) * 2018-11-13 2021-11-19 枣庄学院 联苯多取代1,2,5,6-四氢吡啶化合物及其合成方法与应用

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2662355B1 (fr) * 1990-05-22 1994-11-10 Sanofi Sa Utilisation de la 1-[2-(2-naphtyl)ethyl]-4-(3-trifluoromethylphenyl)-1,2,3,6-tetrahydropyridine pour la preparation de medicaments destines au traitement de troubles cerebraux et neuronaux.
US5453428A (en) * 1991-02-14 1995-09-26 The Mount Sinai School Of Medicine Of The City Of New York Method and composition for the treatment of apathy-amotivation syndrome
EP0813416B1 (en) * 1995-03-06 2005-05-25 Interneuron Pharmaceuticals Incorporated Reduction of infarct volume using citicoline
FR2736053B1 (fr) * 1995-06-28 1997-09-19 Sanofi Sa Nouvelles 1-phenylalkyl-1,2,3,6-tetrahydropyridines

Also Published As

Publication number Publication date
JP2001523642A (ja) 2001-11-27
PL340500A1 (en) 2001-02-12
ID24933A (id) 2000-08-31
EP1030671A1 (fr) 2000-08-30
DZ2649A1 (fr) 2004-12-28
PL194597B1 (pl) 2007-06-29
EA200000412A1 (ru) 2000-12-25
CA2309966A1 (en) 1999-05-27
CN1285742A (zh) 2001-02-28
HUP0100098A3 (en) 2001-12-28
EA003255B1 (ru) 2003-02-27
SK7112000A3 (en) 2000-10-09
KR20010032099A (ko) 2001-04-16
EE200000290A (et) 2001-06-15
CN1243540C (zh) 2006-03-01
CO4980891A1 (es) 2000-11-27
KR100599350B1 (ko) 2006-07-12
IL136122A0 (en) 2001-05-20
BG104428A (en) 2001-08-31
BG64819B1 (bg) 2006-05-31
IL136122A (en) 2006-07-05
IS5482A (is) 2000-05-09
AU743228B2 (en) 2002-01-24
SK286040B6 (sk) 2008-01-07
HUP0100098A2 (hu) 2001-07-30
UY25247A1 (es) 2001-05-31
NZ504420A (en) 2003-08-29
SA98190747B1 (ar) 2006-11-04
WO1999025363A1 (fr) 1999-05-27
TW585766B (en) 2004-05-01
EE04235B1 (et) 2004-02-16
BR9814035A (pt) 2000-09-26
MY120461A (en) 2005-10-31
NO20002450D0 (no) 2000-05-11
AU1160999A (en) 1999-06-07
TR200001262T2 (tr) 2001-01-22
OA11464A (en) 2003-11-18

Similar Documents

Publication Publication Date Title
DE69219378D1 (de) Feingiessverfahren und Zusammensetzung des Modells
HUP0103920A3 (en) Methods and compositions for the prevention and treatment of anemia
DE59306638D1 (de) Verfahren zur Herstellung von 2,2,6,6-Tetramethylpiperidin-N-oxyl und in seiner 4-Stellung substituierten Derivaten
SI0734260T1 (sl) Paroksetinske tablete in postopek za njihovo pripravo
AU2001239052A1 (en) Compositions for prevention and treatment of dementia
DE69826811D1 (de) Zusammensetzungen für die Verwendung bei der Behandlung und Prävention von Hyperurikämie
IL145301A0 (en) 1-arenesulfonyl-2-aryl-pyrrolidine and piperidine derivatives for the treatment of cns disorders
NO982712D0 (no) FremgangsmÕter og mellomprodukter for fremstilling av 1-benzyl-4-((5,6-dimetoksy-1-indanon)-2-yl)metylpiperidin
NO20002450L (no) Sammenstilling av aktive bestanddeler, særlig tetrahydropyridiner og acetylcholinesterase-inhiberende midler, for behandling av senil demens av Alzheimer-type
HUP9900927A3 (en) Substituted 4-(1h-benzimidazol-2-yl-amino)piperidines useful for the treatment of allergic diseases
DE69300062D1 (de) Verfahren zur Herstellung von N-Methoxyderivate von 4-Hydroxy-2,2,6,6-Tetramethylpiperidin und 2,2,6,6-Tetramethyl-4-Piperidon.
IL131085A0 (en) The use of levobupivacaine or ropivacaine in treating migraine
EP0714890A3 (de) Verfahren zur Herstellung von 4-Amino-2,2,6,6-tetramethyl-piperidin
HU9800396D0 (en) Pharmaceutical composition for treating dementia
HUT74615A (en) 2,3-cyclic-condensed-1,4-dihydro-pyridine derivatives, process for producing them and pharmaceutical compositions containing the same
HU9800511D0 (en) Process for producing 4-{4-[4-(hydroxy-diphenyl)-1-piperidinyl]-1-hydroxy-butyl}-alpha-alpha-dimethyl-phenyl-acetic.acid and phosphorylized derivatives thereof
IL128095A0 (en) Formulation for the treatment and/or prophylaxis of dementia
GR3033316T3 (en) Substituted 4-(6-fluoro-[1H]-indol-3-yl)-1,2,3,6-tetrahydropyridine for the treatment of CNS-disorders
HK1028354A (en) Combination of active principles, in particular of tetrahydropyridins and acetylcholinesterase inhibiting agents, for treating senile dementia such as alzheimer dementia
ZA989955B (en) Combination of active ingredients for the treatment of senile dementia of the alzheimer type
SG74735A1 (en) Pyridyl and piperidyl esters of polyalkylphenoxyalkanols and fuel compositions containing the same
KR100248098B1 (en) Pharmaceutical composition for the treatment of dementia
NO941134D0 (no) 1,2,5,6-tetrahydropyridin-derivat, fremgangsmåte for dets fremstilling, og dets terapeutiske anvendelser
CA2103805A1 (en) Use of lacidipine for the treatment of arteriosclerosis
IL120008A0 (en) (1H-indol-4-YL)-piperidine or tetrahydropyridine ethylamines and ethylcarboxamides and pharmaceutical compositions containing them